|Bid||51.03 x 800|
|Ask||0.00 x 1000|
|Day's Range||51.47 - 52.58|
|52 Week Range||36.48 - 58.25|
|Beta (5Y Monthly)||0.78|
|PE Ratio (TTM)||38.24|
|Earnings Date||Nov 01, 2021 - Nov 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.50|
Subscribe to Yahoo Finance Plus to view Fair Value for EGRXLearn more
Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
WOODCLIFF LAKE, N.J., September 07, 2021--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Judi Ng-Cashin, Chief Medical Officer, and will feature other guest speakers, to discuss the CAL02 opportunity, the current treatment landscape and the unmet medical need in treating patients with severe pneumonia as follows: